David M. Kendall

David M. Kendall

Chief Tech/Sci/R&D Officer at ZEALAND PHARMA A/S

62 year
Health Technology
Consumer Services
Commercial Services

Profile

David M.
Kendall
is currently the Chief Medical Officer at Zealand Pharma A.
Prior to this, he worked as the Chief Medical Officer at MannKind Corp.
from 2018 to 2020, and as the Vice President-Global Medical Affairs at Eli Lilly & Co. from 2011 to 2018.
He also served as the Medical Director at Amylin Pharmaceuticals, Inc. from 2005 to 2008, and as the Medical Director at the International Diabetes Center from 1997 to 2009.
Additionally, he was the Chief Scientific & Medical Affairs Officer at the American Diabetes Association from 2009 to 2011.
Kendall's education includes an undergraduate degree from St. Olaf College in 1983 and a doctorate from the University of Minnesota in 1988.

David M. Kendall active positions

CompaniesPositionStart
ZEALAND PHARMA A/S Chief Tech/Sci/R&D Officer 2022-06-01
All active positions of David M. Kendall

Former positions of David M. Kendall

CompaniesPositionEnd
MANNKIND CORPORATION Chief Tech/Sci/R&D Officer 2020-08-27
ELI LILLY AND COMPANY Corporate Officer/Principal 2018-01-31
Lilly Diabetes Corporate Officer/Principal 2017-12-31
Chief Tech/Sci/R&D Officer 2011-06-30
Chief Tech/Sci/R&D Officer 2009-08-31
See the detail of David M. Kendall's experience

Training of David M. Kendall

St. Olaf College Undergraduate Degree
University of Minnesota Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of David M. Kendall's experience

Connections

100 +

1st degree connections

10

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies3
ELI LILLY AND COMPANY

Health Technology

MANNKIND CORPORATION

Health Technology

ZEALAND PHARMA A/S

Health Technology

Private companies5

Health Technology

Commercial Services

Health Services

Commercial Services

Lilly Diabetes

See company connections
  1. Stock Market
  2. Insiders
  3. David M. Kendall